Top ten medicines and vaccines by Revenue 2020
01
$5,850 million
Prevnar®13 / Prevenar®13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])
02
$5,392 million
Ibrance® (palbociclib)
03
$4,949 million
Eliquis® (apixaban)
04
$2,437 million
Xeljanz® (tofacitinib)
05
$1,350 million
Enbrel® (etanercept)
06
$1,288 million
Vyndaqel®/Vyndamax™ (tafamidis)
07
$1,024 million
Xtandi® (enzalutamide)
08
$919 million
Chantix®/Champix® (varenicline)
09
$819 million
Sutent® (sunitinib malate)
10
$787 million
Inlyta® (axitinib)
Top ten medicines and vaccines by Revenue 2020
01
$5,850 million
Prevnar®13 / Prevenar®13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])
02
$5,392 million
Ibrance® (palbociclib)
03
$4,949 million
Eliquis® (apixaban)
04
$2,437 million
Xeljanz® (tofacitinib)
05
$1,350 million
Enbrel® (etanercept)
06
$1,288 million
Vyndaqel®/Vyndamax™ (tafamidis)
07
$1,024 million
Xtandi® (enzalutamide)
08
$919 million
Chantix®/Champix® (varenicline)
09
$819 million
Sutent® (sunitinib malate)
10
$787 million
Inlyta® (axitinib)
skip
Pfizer's ESG Report
Our Environmental, Social and Governance (ESG) report represents a new chapter in Pfizer’s commitment to enhance stakeholder awareness of our priority ESG issues and disclose how our performance on non-financial metrics is contributing to long-term value creation and a sustainable, responsible and patient-centric business model.
Download the report